ADMA Biologics (ADMA)
Manufactures plasma-derived immune globulins for primary immune deficiency and hepatitis B exposure.
$9.49
vs last close−0.32 (−3.26%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67 | 74 | 82 | 107 | 120 | 118 | 115 | 122 | 134 | 139 | 114 | 124 |
| Cost of revenue | 43 | 43 | 43 | 50 | 60 | 54 | 54 | 55 | 59 | 50 | 34 | 38 |
| Gross profit | 25 | 31 | 39 | 57 | 60 | 63 | 61 | 67 | 76 | 89 | 81 | 86 |
| 16 | 17 | 17 | 18 | 20 | 25 | 26 | 24 | 25 | 26 | 30 | 34 | |
| Research & development | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 3 | 6 |
| Selling, general & administrative | 15 | 16 | 16 | 17 | 19 | 23 | 24 | 22 | 23 | 24 | 27 | 27 |
| Other expenses | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| Operating income | 9 | 14 | 22 | 39 | 40 | 38 | 35 | 43 | 51 | 63 | 50 | 52 |
| −6 | −32 | −3 | −3 | −3 | −4 | −1 | −3 | −3 | −1 | 7 | −2 | |
| Interest income | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| Interest expense | 6 | 6 | 4 | 4 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 3 |
| Other non-operating income | 0 | 26 | 0 | 0 | −1 | 1 | −1 | 1 | 2 | 0 | −9 | −1 |
| Income before tax | 3 | −18 | 18 | 36 | 37 | 35 | 33 | 40 | 48 | 62 | 57 | 50 |
| Income tax expense | 0 | 0 | 1 | 4 | 1 | −77 | 7 | 6 | 11 | 12 | 12 | 12 |
| Net income from continuing operations | 3 | −18 | 18 | 32 | 36 | 112 | 27 | 34 | 36 | 49 | 45 | 38 |
| Net income | 3 | −18 | 18 | 32 | 36 | 112 | 27 | 34 | 36 | 49 | 45 | 38 |
| EPS, basic | $0.01 | −$0.08 | $0.08 | $0.14 | $0.15 | $0.47 | $0.11 | $0.14 | $0.15 | $0.21 | $0.19 | $0.17 |
| EPS, diluted | $0.01 | −$0.08 | $0.08 | $0.13 | $0.15 | $0.46 | $0.11 | $0.14 | $0.15 | $0.20 | $0.19 | $0.16 |
| Weighted average shares, basic | 225 | 226 | 229 | 232 | 235 | 236 | 238 | 241 | 239 | 238 | 236 | 228 |
| Weighted average shares, diluted | 234 | 226 | 236 | 242 | 245 | 246 | 245 | 249 | 245 | 244 | 240 | 230 |
| EBITDA | 11 | −9 | 24 | 42 | 42 | 40 | 37 | 44 | 51 | 65 | 61 | 57 |
| Depreciation & amortization | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 |
| EBIT | 9 | −11 | 22 | 40 | 40 | 38 | 35 | 42 | 49 | 63 | 59 | 54 |